Sutro Biopharma (STRO)

• Market cap: $393M
• 1 day: -1.17%
• 5 days: 3.17%
• 1 month: -28.85%
• 3 months: -31.59%
• 6 months: 52.02%
• Year to date: 116.51%
• 1 year: 177.87%
• 5 years: -86.8%
• 10 years: -84.39%
• Sector: Healthcare
• Industry: Biotechnology

About: Sutro Biopharma Inc is a clinical-stage drug discovery, development, and manufacturing company. The company manufactures next-generation protein therapeutics for cancer and autoimmune disorders through its proprietary integrated cell-free protein synthesis platform, XpressCF. Products offered by the company include STRO-001 for patients with multiple myeloma and lymphoma and STRO-002 for the treatment of ovarian and endometrial cancers. Company's wholly-owned product candidate is STRO-004, a single homogeneous ADC directed against tissue factor which are developing for the treatment of solid tumors. The company also pipeline contains STRO-006, STRO-00X, STRO-00Y, STRO-003, VAX24, VAX31, and Others.

Employees: 133